Your browser doesn't support javascript.
A new horizon for the old antibacterial drug clofoctol.
Bailly, Christian; Vergoten, Gérard.
  • Bailly C; OncoWitan, Lille (Wasquehal), 59290, France. Electronic address: christian.bailly@oncowitan.com.
  • Vergoten G; University of Lille, Inserm, INFINITE - U1286, Institut de Chimie Pharmaceutique Albert Lespagnol (ICPAL), Faculté de Pharmacie, 3 rue du Professeur Laguesse, BP-83, F-59006, Lille, France.
Drug Discov Today ; 26(5): 1302-1310, 2021 05.
Article in English | MEDLINE | ID: covidwho-1077854
ABSTRACT
The synthetic antibacterial drug clofoctol (CFT) has long been used to treat respiratory tract infections in Europe. In recent years, the drug was found to target two biologically important proteins, the Cdc7/Dbf4 protein kinase complex and the mRNA-binding protein cold shock domain containing E1 (CSDE1), also known as upstream-of-N-Ras protein (UNR). These interactions are at the origin of the antitumor activity of CFT, recently evidenced in prostate cancer and neuroglioma. Drug-protein binding models provide a structural basis to guide the design of more potent anticancer compounds. A renewed interest in CFT can be anticipated for the treatment of cancers, and possibly Coronavirus 2019 (COVID-19).
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Drug Repositioning / COVID-19 Drug Treatment / Anti-Bacterial Agents / Neoplasms / Antineoplastic Agents Limits: Animals / Humans Language: English Journal: Drug Discov Today Journal subject: Pharmacology / Drug Therapy Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Drug Repositioning / COVID-19 Drug Treatment / Anti-Bacterial Agents / Neoplasms / Antineoplastic Agents Limits: Animals / Humans Language: English Journal: Drug Discov Today Journal subject: Pharmacology / Drug Therapy Year: 2021 Document Type: Article